Log in to WhatsApp Web for simple, reliable and private messaging on your desktop. Send and receive messages and files with ease, all for free. De novo metastatic hormone-sensitive prostate cancer usually has a dismal prognosis, which has slightly improved in recent years thanks to the introduction of new hormonal agents and chemotherapy combined with androgen deprivation therapy from the Mar 12, 2024 · Overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) has improved in clinical trials over the last 20 years. 1, 2 It is unclear whether new treatments have translated to improvements in survival rates in clinical practice. We sought to quantify trends in OS among patients with newly diagnosed de novo (synchronous) mHSPC in 2 national registries in the United States Sep 9, 2024 · Prostate cancer treatments paradigms are in continuous evolution, especially in the metastatic setting. In this context, the Genito-Urinary Group of Italian Association of Radiotherapy and Clinical Oncology aimed to create a consensus on radiation therapy indication in de novo metastatic hormone-sensitive prostate cancer both on primary tumor and metastatic sites. Jul 16, 2025 · The treatment of metastatic hormone-sensitive prostate cancer has evolved rapidly, with the emergence of doublet and triplet therapies transforming outcomes. However, these advances bring new complexity and shift the clinical focus from intensification to personalization. Recent evidence, including major data presented at the 2025 ASCO Annual Meeting, on molecular profiling, biomarkers, and AI Newly presenting or de novo metastatic hormone-sensitive prostate cancer (mHSPC) accounts for 5% to 10% of all prostate cancer (PC) diagnoses, but it is responsible for nearly 50% of PC-related deaths. 1 De novo mHSPC is characterized by an aggressive course with faster development of castration resistance and worse overall survival (OS) in Dr. Karim Fizazi delved into why local treatment still

matters for high-volume de novo metastatic hormone-sensitive prostate cancer. Dr. Fizazi highlighted that in patients with high-volume de novo metastatic hormone-sensitive prostate cancer (mHSPC), a key concern is managing severe local symptoms of metastatic disease. The median age of presentation of de novo metastatic prostate cancer based on registry data is 73–76 years [24 – 26], which is significantly higher than the age of the men recruited in all of the clinical trials. Mar 20, 2023 · Annually, >1.2 million new cases of prostate cancer are diagnosed and global prostate cancer-related deaths exceed 350 000 per annum, making it one of the leading causes of cancer-associated death in men.1 Despite major improvements in the systemic treatment of advanced prostate cancer, metastatic prostate cancer remains an incurable disease with an overall survival (OS) of only 30% at 5 years May 8, 2025 · Key Points Question How has treatment for and survival of metastatic hormone-sensitive prostate cancer (mHSPC) changed over time? Findings In a cross-sectional study of 6216 veterans with de novo mHSPC, the use of combination therapy increased and was associated with longer overall survival. There was no difference in overall survival for veterans with high-volume disease treated with androgen Explain the role of the PI3K/AKT pathway in prostate cancer biology. Explore collaborations between urologists, oncologists, radiologists, and other healthcare professionals in managing de novo mHSPC. Employ strategies to manage and mitigate common adverse events associated with AKT inhibitors and other therapies used in mHSPC.